Regulatorische Updates
25. Sept. 2026•1 Min. Lesezeit
FDA Discontinues Testosterone Enanthate Injectable Products (ANDA083667)
The FDA has discontinued two injectable testosterone enanthate products from Watson Labs, listed under ANDA083667.
Regulatorische Updates
19. Sept. 2026•1 Min. Lesezeit
FDA Accepts ANDA084026 for Watson Labs' Chlorothiazide 500 mg Oral Tablet (Discontinued)
The FDA has processed application ANDA084026 for Watson Labs' oral chlorothiazide 500 mg tablet, currently listed as discontinued.
Regulatorische Updates
19. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA 085767 for Phendimetrazine Tartrate 35 mg Tablet (Watson Labs)
The FDA has approved ANDA 085767 for a 35 mg oral tablet of phendimetrazine tartrate submitted by Watson Labs; the product is listed as discontinued.
Regulatorische Updates
16. Sept. 2026•1 Min. Lesezeit
FDA Approves Methyclothiazide Tablet (ANDA 088750)
The FDA has approved ANDA 088750 for a 2.5 mg oral tablet of methyclothiazide submitted by Watson Labs; the product is listed as discontinued.
Regulatorische Updates
15. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA 085231 for Pyrilamine Maleate Oral Tablet by Watson Labs
The FDA granted approval for ANDA 085231, an oral tablet containing 25 mg pyrilamine maleate, submitted by Watson Labs. The product is listed as discontinued.
Regulatorische Updates
13. Sept. 2026•1 Min. Lesezeit
FDA Lists Diphenhydramine Hydrochloride Injection (ANDA083533) as Discontinued
Watson Labs' diphenhydramine hydrochloride injectable (product 001) is recorded by the FDA under ANDA083533 as discontinued and not a reference drug.
Regulatorische Updates
13. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA081213 for ESTROPIPATE Oral Tablet
The FDA has granted approval (ANDA081213) for Watson Labs' ESTROPIPATE 0.75 mg oral tablet, with several labeling and manufacturing submissions approved.
Regulatorische Updates
10. Sept. 2026•1 Min. Lesezeit
FDA Lists Watson Labs' COBAVITE Injection (ANDA083064) as Discontinued
FDA records indicate that Watson Labs' injectable product COBAVITE, containing 1 mg/mL cyanocobalamin, is listed as discontinued under ANDA083064.
Regulatorische Updates
9. Sept. 2026•1 Min. Lesezeit
FDA Issues ANDA Approval for Watson Labs' Procaineamide Hydrochloride Oral Capsule (ANDA083795)
The FDA has approved an ANDA (ANDA083795) for Watson Labs' oral capsule containing 250 mg of procaineamide hydrochloride. The product is listed as discontinued.
Regulatorische Updates
9. Sept. 2026•1 Min. Lesezeit
FDA Announces Discontinuation of Watson Labs Potassium Chloride Injection (ANDA 086210)
The FDA records show that Watson Labs' potassium chloride injectable (3 mEq/mL) under ANDA 086210 is listed with a discontinued marketing status.
Regulatorische Updates
9. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA085790 for Isoniazid 100 mg Tablet by Watson Labs
The FDA has approved ANDA085790 for an oral 100 mg Isoniazid tablet submitted by Watson Labs. The product is currently listed as discontinued.
Regulatorische Updates
9. Sept. 2026•1 Min. Lesezeit
FDA Lists ANDA087397 for Watson Labs BETHANECHOL CHLORIDE Tablet (Discontinued)
FDA records ANDA087397 for Watson Labs' oral tablet BETHANECHOL CHLORIDE 50 mg, currently marked discontinued.